Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody - Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile
Favorite
Share
More Options
12

Open in WPS to view all 12 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
